ASH Guidelines: Optimal ALL Management for Adolescents & Young Adults

Modern guidelines from the American Society of Hematology (ASH) aim to standardize treatment approaches for adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL), a blood cancer that historically presents unique challenges in this age group. Published simultaneously in Blood Advances, the guidelines address both frontline treatment strategies and management of relapsed or refractory disease, offering a framework for clinicians, particularly those practicing outside of major academic centers.

Approximately 6,100 new cases of ALL are diagnosed annually in the United States, with around 20% occurring in AYAs, defined as individuals aged 15 to 39 years. While childhood ALL generally has a favorable prognosis, with over 90% achieving long-term remission, treatment outcomes for AYAs have been more variable. These new recommendations seek to bridge the gap between pediatric and adult treatment protocols, acknowledging the distinct biological and psychosocial factors impacting this patient population.

Unique Challenges in AYA ALL Treatment

Historically, research indicated that AYAs treated by pediatric hematologists/oncologists tended to fare better than those treated by clinicians primarily focused on adult hematologic malignancies. This observation sparked debate, prompting the CALGB 10403 trial, which demonstrated improved survival with a pediatric-inspired treatment regimen for newly diagnosed ALL in this age group. However, AYAs often face a higher risk of high-risk disease biology and treatment-related toxicities, necessitating a nuanced approach.

“This is a unique group of patients with different needs, so these guidelines are exceptionally important — especially for clinicians who practice outside of academic centers and perhaps don’t see as much ALL,” explained Anjali Advani, MD, staff physician at Cleveland Clinic Taussig Cancer Institute and co-author of the guidelines. “This provides a framework for those physicians and gives them valuable insights.”

Frontline Management Recommendations

The ASH guidelines emphasize that pediatric-inspired regimens can improve survival rates for AYAs compared to traditional adult-focused protocols. Key recommendations include the continued use of asparaginase as a cornerstone of therapy, alongside careful attention to premedication, monitoring, and management of its associated adverse events. The guidelines also suggest a re-evaluation of the role of allogeneic transplant in first remission, noting that current evidence does not strongly support its routine use for AYAs.

Beyond the medical aspects, the guidelines highlight the importance of addressing the unique psychosocial and developmental needs of AYAs. Shared decision-making and tailored supportive care strategies are crucial, recognizing that this age group may have different priorities and challenges compared to children or older adults. For example, young adults may be balancing treatment with education, employment, or family responsibilities.

Looking ahead, Advani anticipates that the integration of immunotherapies into frontline treatment may further refine these recommendations. “Some of the recommendations may change over time as we continue to incorporate immunotherapies into upfront therapy, particularly for B-cell ALL,” she noted. Research is also underway to better understand adherence to maintenance therapy among young adults and its impact on outcomes.

Navigating Relapsed or Refractory ALL

When ALL returns after initial treatment (relapsed) or doesn’t respond to treatment in the first place (refractory), the prognosis for AYAs is generally poorer than for children. Traditional therapies often fail to induce durable remission. The ASH guidelines address this challenging scenario with eight treatment recommendations, reflecting a significant shift driven by the advent of immunotherapy.

Immunotherapies like blinatumomab (Blincyto, Amgen) and inotuzumab (Besponsa, Pfizer) are now recommended over traditional chemotherapy, despite limited direct comparisons between these strategies. Chimeric antigen receptor (CAR) T-cell therapy shows promise, but further research is needed to determine the optimal sequencing of CAR-T and other immunotherapies. Decisions regarding allogeneic transplant require individualized assessment and shared decision-making.

The guidelines also emphasize the importance of central nervous system (CNS)-directed therapy, such as intrathecal chemotherapy, for isolated CNS relapse. CNS radiation alone is not recommended.

The Path Forward: Research and Collaboration

The authors acknowledge limitations in the available evidence, noting “low or very low certainty” for many recommendations. The scarcity of studies specifically focused on AYAs with ALL underscores the urgent need for more research in this area. This includes clinical trials and subanalyses designed to address the unique characteristics and challenges of this patient population.

“We find two huge challenges for treating this population — the speed at which the field is evolving and the need to bridge pediatric and adult oncology approaches to treatment,” said Sumit Gupta, MD, PhD, guideline cochair and professor at the University of Toronto. “These guidelines meet both challenges, and our hope is that they will spur additional collaboration between adult and pediatric oncologists to effectively treat these patients.”

The full guidelines are available on the American Society of Hematology website. For more information, Anjali Advani can be reached at [email protected].

Disclaimer: This information is for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.